NCT02421705Recruiting
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 99999999 (estimated)
- First submitted
- 31 Jul 2013
- Start date
- 12 Mar 2010
- Primary completion date
- 31 Jan 2099
- Lead sponsor
- KU Leuven
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT02421705
What you commit to
- Study type: Interventional
- Planned participants: 99999999
- From 12 Mar 2010 to the primary completion date, 31 Jan 2099
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting
Other
- For all groups:
- Abdominal chirurgy (except for an uncomplicated appendectomy)
Who the study is looking for
- For group 1: IBS
- Irritable Bowel Syndrome (IBS) (ROME III criteria)
- No obvious organic explanation for the IBS symptoms
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
- Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
- Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
- diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
- remission is confirmed by at least one sigmoidoscopy
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
- Only for group 3a:
- Rome III criteria for IBS
- Group 4: Healthy controls No abdominal (pain) complaints.
- Group 5: active Crohn's disease
- 1\. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
- Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
- diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
- remission is confirmed by at least one sigmoidoscopy
- Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.